Direxion Daily TSLA Bull 2X Shares vs 22nd Century Group Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $8.03, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). Which is the better fit depends on your goals.
| TSLL | XXII | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $23.03 | $801.00 |
52-Week Low | $6.74 | $3.72 |
Market Cap | — | $1.52M |
Enterprise Value | — | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.05, down 1.95% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $8. Recent news highlights the amplified volatility inherent in this leveraged Tesla ETF, as discussed by 24/7 Wall Street on July 31, 2026.
The outlook for TSLL is heavily dependent on the performance of Tesla stock, with significant risk from daily leverage decay and market volatility. Investment opportunity exists for those betting on short-term Tesla gains, but the structure poses substantial risk of loss even if Tesla's price increases over the long term.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Trailing returns across standard periods
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →